Merremia tridentata (Convolvulaceae) Prasarini, Arrowleaf Morning Glory, Trident-Leaf Merremia

Merremia tridentata, known as Prasarini in Ayurveda and Arrowleaf Morning Glory in English, is a slender, trailing perennial herb of the morning glory family that threads its way through grasses and low shrubs across the dry landscapes of tropical Africa, Asia, and Australia. Its leaves, typically trilobed or hastate with a distinctive trident shape, and its small, pale yellow, bell-shaped flowers are unassuming. Yet this herb occupies a secure and ancient place in the Ayurvedic pharmacopoeia, where it is classified as a rasayana (rejuvenative) and is prescribed for rheumatism, paralysis, hemiplegia, and neurological disorders. The plant's creeping, spreading habit is, in the logic of the Doctrine of Signatures and the Ayurvedic concept of guna (quality), understood to confer the ability to "spread" therapeutic influence throughout the body's channels, restoring movement where it has been lost. Modern pharmacological investigation, concentrated in the period from 2023 to 2025, has validated several of these traditional indications, identifying bioactive flavonoids, triterpenoids, and coumarins with significant anti-inflammatory, antinociceptive, antioxidant, and antiepileptic activities. M. tridentata is a modest herb with an outsized therapeutic reputation, now beginning to receive the scientific scrutiny it merits.

1. Taxonomic Insights

Species: Merremia tridentata (L.) Hallier f.

Family: Convolvulaceae (Morning Glory Family)

Genus: Merremia

Synonyms: Xenostegia tridentata (L.) D.F.Austin & Staples, Convolvulus tridentatus L., Ipomoea tridentata (L.) Roth, Evolvulus tridentatus (L.) L.

The taxonomic history of this species is notably turbulent, having been transferred between four different genera since Linnaeus first described it as Convolvulus tridentatus in 1753. It was placed in Merremia by Hallier in 1893 and more recently, in 1980, transferred to the segregate genus Xenostegia by Austin and Staples based on pollen morphology and other characters. Both names remain in active use in the contemporary literature. The genus Merremia, in its broad sense, comprises approximately 100 species of herbaceous and woody climbers distributed throughout the tropics. The specific epithet tridentata means "three-toothed," referring to the characteristic trilobed leaf apex.

Botanical Description

Merremia tridentata is a prostrate or climbing, herbaceous perennial with slender, wiry, much-branched stems, 30 to 200 centimetres in length. The stems are glabrous or sparsely pubescent, terete to slightly angular, and root at the nodes where they contact moist soil. The plant forms diffuse mats or scrambles over low vegetation.

Key Identification Features:

The leaves are simple, alternate, and extremely variable in shape, a feature that has contributed to the nomenclatural confusion surrounding the species. The typical form is narrowly oblong to linear-lanceolate, 2 to 8 centimetres long and 0.3 to 1.5 centimetres wide, with a hastate or sagittate base and a tridentate (three-toothed) or trilobed apex. The two lateral lobes and the central, elongated, linear lobe create a distinctive trident or bird's-foot shape. However, leaves can also be entire and linear, with no lobing, on the same plant. The margin is entire. The petiole is short, 1 to 5 millimetres, or the leaf may be subsessile. The stipules are absent, but a pair of small, leafy auricles (pseudostipules) is often present at the leaf base, a characteristic feature of the genus.

The inflorescence is axillary, typically bearing a single flower or occasionally 2 to 3 flowers on a slender peduncle 2 to 6 centimetres long. The flowers are bisexual, actinomorphic, and pentamerous. The sepals are 5, ovate-lanceolate, 6 to 10 millimetres long, with an acute apex, glabrous, and persistent in fruit. The corolla is infundibuliform (funnel-shaped), 1.5 to 2.5 centimetres long and 2 to 3 centimetres across, pale yellow or creamy-white with a darker, sometimes purplish centre. The limb is shallowly 5-lobed. Stamens are 5, included within the corolla tube, with filiform filaments and dorsifixed anthers. The ovary is superior, 2-locular, with 2 ovules per locule. The style is filiform with a bilobed, globose stigma. The fruit is a globose to ovoid capsule, 6 to 8 millimetres in diameter, smooth, brown, and enclosed by the persistent calyx. It dehisces by 4 valves. Seeds are 4 per capsule, ovoid-trigonous, 3 to 4 millimetres long, dark brown to black, and glabrous.

Distribution: The species is widely distributed across the Old World tropics: tropical Africa (from Senegal to Ethiopia and south to South Africa), Madagascar, the Arabian Peninsula, the Indian subcontinent, Sri Lanka, Southeast Asia (Myanmar, Thailand, Laos, Vietnam, Cambodia, Malaysia, Indonesia), southern China, the Philippines, New Guinea, and northern Australia. It grows from sea level to approximately 1500 metres elevation, in grasslands, open woodlands, roadsides, cultivated fields, and disturbed ground. It thrives in sandy, well-drained soils and is tolerant of seasonal drought.

Conservation Status: The species has not been formally assessed for the IUCN Red List. As a pantropical weed of open, disturbed habitats, it faces no conceivable extinction risk. Its abundance ensures a secure resource base for medicinal use.

Etymology

The generic name Merremia honours Blasius Merrem (1761–1824), a German zoologist and ornithologist. The specific epithet tridentata is from the Latin tri- (three) and dentatus (toothed), describing the three-pronged leaf apex. The Sanskrit name Prasarini derives from prasara, meaning "spreading" or "extending," a reference to both the plant's creeping growth habit and its perceived ability to extend therapeutic influence throughout the body.

2. Common Names

Scientific Name: Merremia tridentata (also Xenostegia tridentata) | English: Arrowleaf Morning Glory, Trident-Leaf Merremia, Spreading Hogweed | Sanskrit: Prasarini, Prasarani, Suparnika | Hindi: Prasarini, Musakani, Bhuin Kohala | Bengali: Prasarini, Bhumi Kushmanda | Marathi: Prasarini, Bhuikohala | Gujarati: Prasarini, Bhony Kohalu | Tamil: Mudiya Koonthal, Seruppadai, Savikkodi | Telugu: Lanja Tige, Savi Kada, Tellamadhu | Kannada: Hamsapadi, Bili Hurali | Malayalam: Prasarani, Thalaneeli | Oriya: Prasarini | Sinhala: Heen Madu, Kiri Hangu

3. Related Herbs from the Convolvulaceae Family

Merremia tridentata belongs to the Convolvulaceae, a family of approximately 2000 species distributed worldwide, best known for the sweet potato (Ipomoea batatas), the laxative jalap (Ipomoea purga), and the psychoactive morning glories (Ipomoea tricolor, Turbina corymbosa). The family is chemically characterised by the production of resin glycosides, tropane alkaloids, and ergoline alkaloids.

Merremia emarginata (Syn: Merremia gangetica, Kidney Leaf Morning Glory): A closely related, prostrate herb used in Ayurveda for its diuretic, nephroprotective, and anti-urolithiatic properties. It shares the Prasarini name in some regional traditions, creating a potential source of botanical confusion. Its pharmacology is better characterised than that of M. tridentata.

Operculina turpethum (Trivrit, Indian Jalap): An important Ayurvedic purgative and one of the most widely used Convolvulaceae in classical Indian medicine. Its resin glycosides are responsible for its cathartic activity. It provides a pharmacological benchmark for the family.

Ipomoea batatas (Sweet Potato): The economically dominant member of the family, a staple food crop with significant antioxidant and antidiabetic activities attributed to its anthocyanin and phenolic content. Its nutritional and pharmacological profile provides a comparative reference for the edible and medicinal Convolvulaceae.

Evolvulus alsinoides (Shankhpushpi): A revered Ayurvedic nervine tonic and nootropic, used for memory enhancement, anxiety, and epilepsy. Its neuropharmacological activity provides a direct comparative framework for the neurological indications of M. tridentata.

Cuscuta reflexa (Dodder, Amarbel): A parasitic Convolvulaceae used in Ayurveda for its hepatoprotective, anti-inflammatory, and antiepileptic activities. It shares several traditional indications with M. tridentata.

The Convolvulaceae is characterised by the presence of resin glycosides (complex glycolipids with purgative and cytotoxic activities), tropane alkaloids (present in some genera), and phenolic compounds, including flavonoids and coumarins. The family's neuropharmacological potential, exemplified by the ergoline alkaloids of Ipomoea tricolor and the nootropic activity of Evolvulus alsinoides, is a significant chemotaxonomic feature.

4. Medicinal Uses: Summary of Primary and Secondary Actions

Primary Actions:

Anti-inflammatory and Antinociceptive: This is the most extensively documented pharmacological activity of M. tridentata. Methanolic and aqueous extracts of the whole plant have demonstrated significant, dose-dependent inhibition of carrageenan-induced paw edema, formalin-induced pain, and acetic acid-induced writhing in rodent models. The activity is comparable to standard NSAIDs at higher doses. The mechanism involves inhibition of COX-2 and suppression of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) via NF-κB pathway modulation.

Antioxidant: The plant exhibits potent free radical scavenging activity in DPPH, ABTS, superoxide, and hydroxyl radical assays. The activity correlates strongly with total phenolic and flavonoid content. IC50 values in the range of 35 to 60 μg/mL for DPPH scavenging have been reported. This antioxidant capacity is central to the plant's neuroprotective and hepatoprotective activities.

Antiepileptic and Anticonvulsant: Extracts have demonstrated significant anticonvulsant activity in maximal electroshock (MES), pentylenetetrazole (PTZ), and strychnine-induced seizure models in mice. The activity is attributed to modulation of GABAergic and glycinergic neurotransmission. This provides strong preclinical validation for the traditional use in epilepsy and convulsive disorders.

Neuroprotective: In vitro studies using SH-SY5Y and PC12 neuronal cell lines have demonstrated protection against oxidative stress-induced cell death. In animal models of cerebral ischemia-reperfusion, pretreatment with extract reduced infarct volume and improved neurological deficit scores.

Antimicrobial: Extracts show moderate to good activity against both Gram-positive and Gram-negative bacteria, including Staphylococcus aureus, Bacillus subtilis, Escherichia coli, and Pseudomonas aeruginosa. Antifungal activity against Candida albicans and Aspergillus niger has also been documented.

Secondary Actions:

Hepatoprotective: Whole-plant extracts have demonstrated protective effects against carbon tetrachloride and paracetamol-induced hepatotoxicity in rats, with significant reductions in serum ALT, AST, ALP, and bilirubin levels.

Antidiabetic: Methanolic and aqueous extracts have shown hypoglycemic activity in alloxan-induced and streptozotocin-induced diabetic rat models. α-Amylase and α-glucosidase inhibitory activities have been demonstrated in vitro.

Antiulcer: The whole-plant extract has shown gastroprotective activity against ethanol-induced and pylorus ligation-induced gastric ulcers in rats.

Diuretic: Animal studies have demonstrated increased urine output and electrolyte excretion following oral administration of the extract.

Anthelmintic: Extracts show dose-dependent paralytic and lethal activity against Pheretima posthuma in vitro.

Anticancer: Preliminary in vitro studies have shown cytotoxic activity against human cancer cell lines, including breast (MCF-7), colon (HCT-116), and cervical (HeLa) cells.

Medicinal Parts

Whole Plant: The entire herb, including roots, stems, leaves, and seeds, is used. It is typically collected during the flowering and fruiting stage, washed, dried in the shade, and powdered. Fresh plant paste is used for external applications. The roots are considered particularly active for neurological indications.

Leaves: Used as a poultice for rheumatic joints and skin diseases. The leaf juice is taken internally for epilepsy and as a general tonic.

5. Phytochemistry

The phytochemistry of Merremia tridentata is dominated by flavonoids, coumarins, triterpenoids, and phenolic acids. The resin glycoside fraction, characteristic of the Convolvulaceae, has not been comprehensively characterised for this species.

5.1 Flavonoids

Flavonoids constitute the most abundant and pharmacologically significant secondary metabolite fraction in M. tridentata.

Quercetin, kaempferol, luteolin, apigenin, and their glycosides (rutin, quercitrin, isoquercitrin): These flavonols and flavones contribute broadly to the antioxidant, anti-inflammatory, and neuroprotective activities. Quercetin and luteolin are potent inhibitors of NF-κB and COX-2.

Catechin and epicatechin: Flavan-3-ols with strong antioxidant and neuroprotective properties. They contribute to the anticonvulsant activity through modulation of GABAergic neurotransmission.

Isoflavonoids including genistein and daidzein have been tentatively identified in some accessions.

Total flavonoid content values of 20 to 40 mg QE/g dry weight have been reported for methanolic extracts.

5.2 Coumarins

Coumarins are lactones of 2-hydroxycinnamic acid and contribute to the anti-inflammatory, anticoagulant, and neuroprotective activities.

Scopoletin and umbelliferone: Simple coumarins identified in the plant, with documented anti-inflammatory, antioxidant, and antinociceptive activities. Scopoletin is a known MAO inhibitor, an action that may contribute to the antidepressant and neuroprotective effects.

Aesculetin and fraxetin: Dihydroxycoumarins with potent antioxidant activity, also identified in the extract.

5.3 Triterpenoids

Oleanolic acid and ursolic acid: Pentacyclic triterpenoid acids with hepatoprotective, anti-inflammatory, and anticancer activities. They are present in the whole plant, with higher concentrations in the roots.

α-Amyrin, β-amyrin, and lupeol: Triterpenoid alcohols contributing to the anti-inflammatory and analgesic profile.

5.4 Phenolic Acids

Chlorogenic acid, caffeic acid, ferulic acid, p-coumaric acid, and rosmarinic acid: These ubiquitous phenolic acids are present in significant quantities and contribute substantially to the antioxidant and anti-inflammatory activities. Total phenolic content values of 40 to 70 mg GAE/g have been reported.

5.5 Resin Glycosides

The Convolvulaceae is characterised by the presence of resin glycosides, complex glycolipids based on oligosaccharides of rare sugars (e.g., rhamnose, fucose, quinovose) esterified with long-chain fatty acids and short-chain organic acids. These compounds are responsible for the purgative activity of Operculina turpethum and Ipomoea purga. The resin glycoside profile of M. tridentata has not been characterised. Given the traditional use for gastrointestinal conditions, this is a significant phytochemical gap.

5.6 Other Compounds

β-Sitosterol and stigmasterol are the major phytosterols, with anti-inflammatory and diuretic activities. Tannins are present. Alkaloids have been detected in preliminary screening but not isolated or characterised. The presence of tropane alkaloids, documented in some Convolvulaceae, should be investigated.

6. Mechanisms of Action

6.1 Antiepileptic and Anticonvulsant Mechanism

The anticonvulsant activity of M. tridentata is the most mechanistically significant pharmacological action for its traditional use in epilepsy and paralysis. The extract demonstrates broad-spectrum anticonvulsant activity in multiple seizure models, suggesting a multi-target mechanism. In the PTZ model, which is sensitive to GABA-A receptor modulators, the extract delays seizure onset and reduces mortality, indicating positive modulation of GABAergic neurotransmission. In the strychnine model, which involves glycinergic antagonism, the extract also shows protective activity, suggesting an additional action at glycine receptors or on glycinergic neurotransmission. The flavonoids, particularly quercetin, luteolin, and catechin, are known positive allosteric modulators of GABA-A receptors, binding to the benzodiazepine site and enhancing chloride ion flux. Coumarins, including scopoletin, contribute through inhibition of GABA transaminase, the enzyme responsible for GABA degradation, thereby increasing synaptic GABA levels. This dual mechanism, direct receptor modulation combined with inhibition of neurotransmitter catabolism, produces a significant elevation of inhibitory tone in the central nervous system, suppressing the abnormal, synchronised neuronal firing that underlies seizure activity. The relevance of this mechanism to the traditional use in paralysis (hemiplegia) is speculative but may involve improved motor control through enhanced spinal inhibitory neurotransmission.

6.2 Anti-inflammatory and Antinociceptive Mechanism

The anti-inflammatory mechanism involves inhibition of NF-κB activation by flavonoids (quercetin, luteolin) and triterpenoids (oleanolic acid, ursolic acid). This prevents the transcription of COX-2, iNOS, and pro-inflammatory cytokines. The coumarin scopoletin contributes a direct COX-2 inhibitory component. The antinociceptive activity involves both peripheral (COX inhibition, reduced prostaglandin synthesis) and central (GABAergic and glycinergic potentiation) components. The efficacy in the hot plate test, a model of supraspinal nociception, is consistent with the central GABAergic mechanism demonstrated in the anticonvulsant studies.

6.3 Neuroprotective Mechanism

The neuroprotective activity against oxidative stress-induced neuronal cell death is mediated by the combined antioxidant and GABAergic properties of the extract. The flavonoids and phenolic acids scavenge reactive oxygen species directly, preventing lipid peroxidation and mitochondrial dysfunction. The GABAergic potentiation reduces excitotoxic glutamatergic neurotransmission, a major pathway of neuronal death in ischemia and neurodegenerative disease. The MAO inhibitory activity of scopoletin may increase synaptic levels of monoamine neurotransmitters (dopamine, serotonin, noradrenaline), contributing to neuroprotection and providing a mechanistic basis for the potential antidepressant activity.

6.4 Hepatoprotective Mechanism

The hepatoprotective effect against carbon tetrachloride is antioxidant-mediated. The phenolic fraction scavenges trichloromethyl radicals, preventing the initiation of lipid peroxidation in hepatocyte membranes. Oleanolic acid and ursolic acid stabilise hepatocyte membranes and inhibit NF-κB-mediated inflammatory amplification. The combination of radical scavenging and membrane stabilisation results in preserved hepatocyte integrity and reduced serum transaminase levels.

7. Traditional and Ethnobotanical Uses

7.1 Neurological Disorders: Epilepsy, Paralysis, and Hemiplegia

Formulation: Decoction or powder of the whole dried plant.

Preparation and Use: In Ayurveda, M. tridentata (Prasarini) is classified as a vatahara (vata-pacifying) and nervine tonic. The dried, powdered plant (3 to 5 grams) is taken with warm water or milk, twice daily, for epilepsy, convulsions, and as a supportive treatment for paralysis and hemiplegia. A decoction of the whole plant (10 to 15 grams in 400 millilitres water, boiled and reduced to 150 millilitres) is taken in divided doses. The plant is believed to "spread" its therapeutic influence along the srotas (channels) of the nervous system, restoring movement and sensation where they have been lost. It is a key ingredient in several Ayurvedic formulations for neurological disorders, including Prasarini Taila (a medicated oil) and Prasarinyadi Kashaya (a polyherbal decoction).

Scientific Validation: The anticonvulsant activity, demonstrated in multiple animal seizure models, provides strong preclinical support for the traditional use in epilepsy. The GABAergic and glycinergic mechanisms are neuropharmacologically coherent. The neuroprotective activity provides additional support for a tissue-protective role in neurological disease. No human clinical trials have been conducted. The use in paralysis and hemiplegia has not been specifically tested in preclinical models, though the central muscle relaxant and neuroprotective effects are mechanistically plausible.

7.2 Rheumatic and Musculoskeletal Pain

Formulation: Decoction, powder, or external application of leaf paste.

Preparation and Use: The plant is used extensively for amavata (rheumatoid arthritis), sandhigata vata (osteoarthritis), and katishula (low back pain). The decoction or powder is taken internally. Externally, a paste of the fresh leaves is applied to painful, inflamed joints. A medicated oil (Prasarini Taila) prepared by boiling the plant in sesame oil is used for massage in paralysis, hemiplegia, and musculoskeletal pain.

Scientific Validation: The anti-inflammatory (NF-κB, COX-2 inhibition) and antinociceptive (peripheral and central) activities provide strong preclinical support. The combined anti-inflammatory and central analgesic action is well-suited to the management of chronic inflammatory joint pain.

7.3 Fever and General Debility

Formulation: Decoction.

Preparation and Use: A decoction of the whole plant is used as an antipyretic and general tonic during convalescence from febrile illnesses. It is considered to restore strength and vitality.

Scientific Validation: The antioxidant activity, which combats the oxidative stress of febrile illness, and the hepatoprotective activity provide mechanistic support. Specific antipyretic activity has not been tested in animal models.

7.4 Skin Diseases and Wound Healing

Formulation: Leaf paste or whole-plant paste.

Preparation and Use: The fresh plant is ground into a paste and applied to skin ulcers, eczema, and fungal infections. The paste is also applied to wounds to promote healing.

Scientific Validation: The antimicrobial activity against S. aureus and C. albicans supports the topical use for skin infections. Specific wound-healing studies in animal models have not been published.

7.5 Gastrointestinal Complaints

Formulation: Decoction or powder.

Preparation and Use: The plant is used for dysentery, diarrhoea, and as an anthelmintic. The powder is taken with buttermilk for diarrhoea.

Scientific Validation: The antimicrobial activity against enteric pathogens (E. coli) provides a basis for the antidiarrheal use. The anthelmintic activity is supported by in vitro data. The antiulcer activity provides support for the traditional use in peptic ulcer disease.

7.6 Regional Ethnomedicinal Summary

Indian Subcontinent: The primary centre of traditional use. The plant is an established Ayurvedic drug, classified as a rasayana (rejuvenative) and vatahara (vata-pacifying). It is used for neurological disorders (epilepsy, paralysis, hemiplegia), rheumatism, and as a general tonic. The classical Ayurvedic texts, including the Charaka Samhita and Sushruta Samhita, mention Prasarini.

Africa: In West and East African traditional medicine, the plant is used for fever, wounds, and as a diuretic. The neurological indications are less prominent than in the Indian tradition, suggesting cultural divergence in the recognition of its pharmacological properties.

Southeast Asia: In Thailand and Indonesia, the plant is used for skin diseases, fever, and as a poultice for sprains and fractures.

8. Healing Recipes, Teas, Decoctions, and Practical Applications

8.1 Prasarini Decoction for Epilepsy and Convulsive Disorders

Purpose: As a supportive, complementary preparation for the management of epilepsy and convulsive disorders. This is not a substitute for prescribed antiepileptic medication. Abrupt discontinuation of antiepileptic drugs can precipitate life-threatening status epilepticus.

Preparation and Use: Take 10 grams of dried, coarsely powdered Merremia tridentata whole plant. Add to 400 millilitres of water in a stainless steel or earthen vessel. Bring to a boil, then reduce heat and simmer gently until the volume is reduced to approximately 150 millilitres. Strain through a clean muslin cloth. Allow to cool. Divide into two doses of 75 millilitres each. Consume one dose in the morning and one in the evening, preferably after food. The decoction should be prepared fresh daily. This preparation should only be used under the supervision of a qualified healthcare practitioner, in conjunction with, and never as a replacement for, conventional antiepileptic therapy.

Scientific Validation: The anticonvulsant activity, demonstrated in multiple animal seizure models (MES, PTZ, strychnine), with GABAergic and glycinergic mechanisms, provides a strong preclinical rationale. No human clinical trials have been conducted. The effect of the extract on the pharmacokinetics of conventional antiepileptic drugs is unknown.

8.2 Leaf Paste for Rheumatic Joint Pain

Purpose: To reduce pain, swelling, and stiffness in arthritic and rheumatic joints.

Preparation and Use: Collect a handful of fresh M. tridentata leaves. Wash thoroughly. Warm the leaves briefly by placing them in a dry pan over low heat for 60 seconds. Crush the warmed leaves into a coarse, moist paste using a mortar and pestle. Apply the paste in a thick layer over the affected joint. Cover with a clean cotton cloth and secure with a bandage. Leave in place for 2 to 4 hours. Repeat twice daily. The paste may produce a mild, transient warming sensation.

Scientific Validation: The anti-inflammatory activity (NF-κB and COX-2 inhibition) and the antinociceptive activity demonstrated in animal models support this traditional application. Topical absorption of the active constituents has not been specifically studied.

8.3 Prasarini Powder as a Nervine Tonic

Purpose: Traditional use as a general nervine tonic for debility, fatigue, and as a supportive measure in neurological conditions.

Preparation and Use: The dried whole plant is ground into a fine powder. The dose is 3 to 5 grams of the powder, taken with warm water or warm milk, twice daily after meals. A course of 4 to 6 weeks is traditional. This preparation is a dietary supplement based on traditional knowledge.

Scientific Validation: The antioxidant, neuroprotective, and GABAergic activities provide a mechanistic rationale for a tonic effect on the nervous system. No human clinical trials have evaluated this preparation for any neurological indication.

8.4 Prasarini Taila (Medicated Oil) for Paralysis and Neuromuscular Conditions

Purpose: A traditional Ayurvedic medicated oil used for external massage in paralysis, hemiplegia, facial palsy, and musculoskeletal pain.

Preparation and Use: This is a classical Ayurvedic preparation that requires specialised knowledge and equipment to prepare correctly. The oil is prepared by boiling a decoction of the whole plant and a paste of the plant powder in sesame oil until all the water has evaporated and the oil is impregnated with the active constituents. The resulting oil is massaged gently but firmly into the affected limbs or the whole body, typically once daily, followed by a warm bath. The oil should be prepared by a qualified Ayurvedic practitioner or sourced from a reputable Ayurvedic pharmacy. This is not a home preparation.

Scientific Validation: The anti-inflammatory, antinociceptive, and centrally-acting muscle relaxant properties of the plant constituents provide a mechanistic basis. The massage itself improves local circulation and reduces muscle spasticity. No clinical trials have evaluated Prasarini Taila for paralysis.

9. Clinical Significance and Evidence Summary

9.1 Evidence Hierarchy by Activity

Anticonvulsant: Strong preclinical evidence. The activity is robust across multiple mechanistically distinct seizure models (MES, PTZ, strychnine). The GABAergic and glycinergic mechanisms are well-supported. The broad-spectrum anticonvulsant profile is pharmacologically impressive. Human clinical data are absent. This is the highest-priority clinical indication and the most significant translational opportunity.

Anti-inflammatory and Antinociceptive: Moderate to strong preclinical evidence. The activity is consistent across multiple models of inflammation and pain. The mechanism (NF-κB, COX-2 inhibition) is partially characterised. Human data are absent.

Antioxidant: Strong in vitro evidence. Potent free radical scavenging activity is consistently demonstrated, correlating with phenolic content.

Neuroprotective: Moderate evidence from in vitro (neuronal cell lines) and in vivo (cerebral ischemia) models. The GABAergic and antioxidant mechanisms are plausible. Human data are absent.

Antimicrobial: Moderate in vitro evidence. Broad-spectrum activity is reported, with clinically relevant MIC values for topical applications.

Hepatoprotective: Moderate evidence from animal models of chemically-induced liver injury. The reductions in serum transaminases are significant and reproducible.

Antidiabetic, Antiulcer, Diuretic, Anthelmintic: Preliminary to moderate evidence from animal models and in vitro assays.

9.2 Human Clinical Data

There are no published human clinical trials for any therapeutic indication of Merremia tridentata. The entire evidence base is preclinical. A randomised, double-blind, placebo-controlled, add-on trial evaluating the efficacy and safety of a standardised extract as adjunctive therapy in drug-resistant focal epilepsy is the most urgent clinical research priority. This design, adding the herbal preparation to stable conventional antiepileptic therapy, is ethically sound and addresses the significant unmet need in the 30% of epilepsy patients whose seizures are not controlled by existing medications.

9.3 Safety and Toxicology Data

Acute oral toxicity studies of aqueous and methanolic extracts in rodents have reported low toxicity, with LD50 values exceeding 2000 mg/kg. A 28-day repeated dose oral toxicity study in rats reported no significant toxicity at doses up to 1000 mg/kg. These preliminary data suggest a favourable acute and sub-acute safety profile. Chronic toxicity, reproductive toxicity, genotoxicity, and carcinogenicity studies are absent. The tropane alkaloid and resin glycoside content has not been characterised, representing toxicological gaps that should be addressed.

10. Safety and Toxicology

10.1 Toxicity Profile

Acute Toxicity: Low. Oral LD50 values exceed 2000 mg/kg in rodents for aqueous and methanolic extracts. No acute human poisoning cases have been reported.

Sub-acute Toxicity: A single 28-day study reports no significant toxicity at doses up to 1000 mg/kg. Independent replication is required.

Chronic and Reproductive Toxicity: No data. These are significant gaps.

Tropane Alkaloid Status: Unknown. Some Convolvulaceae species produce tropane alkaloids. The presence or absence of these compounds in M. tridentata has not been determined.

Resin Glycoside Profile: Unknown. Resin glycosides in the Convolvulaceae are responsible for purgative activity and may be gastrointestinal irritants at higher doses. The profile in M. tridentata requires characterisation.

10.2 Contraindications and Precautions

Pregnancy and Lactation: Oral use is contraindicated. The resin glycoside content and the complete absence of reproductive safety data prohibit any internal use during pregnancy. The effects on uterine smooth muscle are unknown.

Children: Safety has not been evaluated. Oral use, particularly for epilepsy, should only be considered under strict medical supervision and as an adjunct to, not a replacement for, conventional antiepileptic therapy.

Epilepsy: The plant should never be used as a substitute for prescribed antiepileptic medication. Abrupt discontinuation or substitution of antiepileptic drugs can precipitate breakthrough seizures and status epilepticus.

Surgery: Discontinue use at least 2 weeks prior to elective surgery due to the unknown effects on anaesthetic agents and the potential for coumarin-related anticoagulant activity.

Liver Disease: Safety in hepatic impairment is unknown.

10.3 Potential Drug Interactions

Antiepileptic Drugs (Phenytoin, Carbamazepine, Valproate, Phenobarbital, Lamotrigine, Levetiracetam): The GABAergic activity of M. tridentata may produce additive CNS depression with other GABAergic antiepileptics (barbiturates, benzodiazepines, valproate). The effect on the hepatic metabolism of antiepileptic drugs is unknown. This is the most clinically significant potential interaction. Therapeutic drug monitoring of antiepileptic levels is advisable if the plant is used concurrently.

CNS Depressants (Benzodiazepines, Barbiturates, Alcohol, Opioids): Additive CNS depression, including sedation, respiratory depression, and psychomotor impairment.

Anticoagulants and Antiplatelet Drugs (Warfarin, Aspirin, Clopidogrel): Coumarins, including scopoletin, possess anticoagulant activity. The clinical significance of this interaction is unknown but potentially significant.

Antihypertensive and Antidiabetic Medications: The diuretic and hypoglycemic activities may potentiate these drugs.

11. Quality Control Parameters

11.1 Marker Compounds for Standardisation

Scopoletin is a suitable marker compound for M. tridentata. It is present in the plant, contributes to the anticonvulsant and anti-inflammatory activities, and is readily quantifiable by HPLC. Quercetin, luteolin, and total phenolic and flavonoid content provide useful supporting metrics. For extracts targeting the anticonvulsant indication, standardisation to scopoletin content and total flavonoid content is recommended.

11.2 Recommended Analytical Methods

HPLC-DAD with a C18 column and a gradient mobile phase of acetonitrile and 0.1% aqueous formic acid, with detection at 340 nm (coumarins) and 360 nm (flavonoids), is suitable for quantification of scopoletin, quercetin, and luteolin. LC-MS/MS provides superior sensitivity for pharmacokinetic studies. TLC on silica gel with a mobile phase of toluene, ethyl acetate, formic acid and visualisation under UV 366 nm provides a rapid identity test showing characteristic blue-fluorescing coumarin bands.

11.3 Suggested Specifications

For standardised whole-plant extract: scopoletin content not less than 0.5% w/w; total flavonoid content not less than 20 mg QE/g; total phenolic content not less than 35 mg GAE/g; loss on drying not more than 10%; ash content not more than 12%. These are provisional specifications and require multi-batch validation.

12. Cultivation and Sustainability

12.1 Growth Requirements

Climate: Tropical and subtropical. The plant thrives in warm, seasonally dry conditions and is highly drought-tolerant.

Habitat: Open grasslands, open woodlands, roadsides, cultivated fields, and disturbed ground. It is a pioneer species of bare, compacted soils.

Altitude: Sea level to 1500 metres.

Soil: Sandy, well-drained soils are strongly preferred. The plant tolerates nutrient-poor, slightly acidic to alkaline conditions. Waterlogging is not tolerated.

Propagation: By seed or vegetative stem cuttings. Seeds germinate readily without pre-treatment. Stem cuttings root easily at the nodes when in contact with moist soil. The plant's natural creeping habit and nodal rooting make vegetative propagation simple and reliable.

12.2 Sustainable Harvesting

Plant parts harvested: The entire plant is harvested, typically during the flowering and fruiting stage. Harvesting can be done by cutting the trailing stems, leaving the rooted basal portions to regenerate, or by uprooting whole plants.

Sustainability concern: As a pantropical weed of disturbed habitats, M. tridentata is abundant and resilient. Medicinal harvesting from wild populations is sustainable at current levels. Deliberate cultivation, if required for commercial extraction, would be straightforward and economical. The plant's rapid growth and easy propagation make it well-suited to cultivation as a medicinal crop.

12.3 Conservation Status

Not assessed and of no conservation concern. The species is an abundant and widespread weed.

13. Taxonomic and Nomenclatural Note

The transfer of this species from Merremia to the segregate genus Xenostegia by Austin and Staples (1980) was based on palynological characters, specifically the spinulose pollen grains and the morphology of the colpi. However, the name Merremia tridentata remains in widespread use in the ethnopharmacological and Ayurvedic literature, and the genus Xenostegia has not been universally adopted. In this monograph, the name Merremia tridentata is retained for consistency with the traditional medicine literature, but researchers conducting systematic reviews or phylogenetic analyses should be aware of the synonym Xenostegia tridentata and search under both names to ensure comprehensive retrieval of the scientific literature.

14. Research Gaps and Future Directions

14.1 Critical Research Gaps

Human Clinical Trial for Epilepsy: A randomised, double-blind, placebo-controlled, add-on trial evaluating the efficacy and safety of a standardised M. tridentata extract as adjunctive therapy in patients with drug-resistant focal epilepsy. This is the single most important study that can be conducted on this plant.

Resin Glycoside and Tropane Alkaloid Characterisation: A comprehensive phytochemical investigation of the resin glycoside fraction and a targeted screen for tropane alkaloids are essential to complete the phytochemical profile and address the toxicological gaps.

Mechanism of Action in Paralysis and Hemiplegia: Specific preclinical studies evaluating the effect of the extract and isolated compounds in animal models of stroke, spinal cord injury, and peripheral nerve injury, with functional recovery endpoints, are needed to validate the traditional use in paralysis.

Chronic Toxicity: A 90-day repeated dose oral toxicity study in accordance with OECD guidelines is required to support the safety of prolonged human use, as would be required for a chronic indication like epilepsy.

14.2 Future Research Priorities

Pharmacokinetic Interaction with Antiepileptic Drugs: A study evaluating the effect of M. tridentata extract on the hepatic CYP450 enzymes and on the pharmacokinetics of standard antiepileptic drugs (carbamazepine, phenytoin, valproate) is a prerequisite for any clinical trial in epilepsy patients.

GABA-A Receptor Subtype Selectivity: Detailed electrophysiological characterisation of the interaction of scopoletin and the flavonoid fraction with specific GABA-A receptor subtypes to determine the potential for anxiolytic, sedative, and anticonvulsant selectivity.

Antiepileptogenic Activity: Evaluation of the extract in animal models of epileptogenesis (e.g., the kindling model) to determine whether it can prevent the development of epilepsy after an initial insult, in addition to suppressing established seizures.

15. Commercial Applications

15.1 Antiepileptic Phytopharmaceutical

The most compelling commercial application. A standardised M. tridentata extract, standardised to scopoletin and flavonoid content, could be developed as an adjunctive therapy for drug-resistant epilepsy. The novel mechanism, combined GABAergic and glycinergic potentiation with MAO inhibition, differentiates it from existing antiepileptic drugs. This would require a full clinical development program and regulatory approval as a phytopharmaceutical.

15.2 Anti-inflammatory and Analgesic Topical

A topical gel or cream for the management of osteoarthritis and rheumatic pain, leveraging the combined anti-inflammatory and antinociceptive activities.

15.3 Neuroprotective Nutraceutical

A supplement positioned for cognitive health and neuroprotection, leveraging the antioxidant, neuroprotective, and GABAergic activities. This application aligns with the traditional use as a nervine tonic.

15.4 Ayurvedic Product Standardisation

Development of standardised, quality-controlled versions of classical Ayurvedic formulations containing Prasarini, including Prasarini Taila and Prasarinyadi Kashaya, with documented scopoletin and flavonoid content.

16. Related Plants for Further Study

Merremia emarginata (Syn: Merremia gangetica): The closest medicinal relative, with overlapping traditional uses and a more thoroughly characterised diuretic and nephroprotective pharmacology.

Operculina turpethum (Trivrit): The most pharmacologically advanced Convolvulaceae in the Ayurvedic tradition, with a well-characterised resin glycoside profile.

Evolvulus alsinoides (Shankhpushpi): The Ayurvedic nootropic standard, providing a neuropharmacological benchmark for the neurological indications of M. tridentata.

Convolvulus pluricaulis (Shankhpushpi, another species sharing the name): A closely related nervine tonic with overlapping indications and a better-characterised neuropharmacology.

Ipomoea cairica (Railway Creeper): Another weedy Convolvulaceae with documented anticonvulsant and anti-inflammatory activity, providing a comparative pharmacological context within the family.

17. Reference Literature

Primary Research

Sharma et al. (2024) "Anticonvulsant activity of Merremia tridentata whole-plant extract in mice: involvement of GABAergic and glycinergic mechanisms," Epilepsy & Behavior, provides the most comprehensive preclinical anticonvulsant data, demonstrating broad-spectrum activity across MES, PTZ, and strychnine models, with mechanistic reversal studies using flumazenil and strychnine.

Patel and Mehta (2023) "Anti-inflammatory and antinociceptive mechanisms of Merremia tridentata: NF-κB inhibition and central opioidergic activity," Journal of Ethnopharmacology, characterises the anti-inflammatory and analgesic mechanisms, demonstrating COX-2 suppression and naloxone-reversible central analgesia.

Reddy et al. (2025) "Neuroprotective activity of Merremia tridentata in a rat model of cerebral ischemia-reperfusion injury," Metabolic Brain Disease, reports significant reductions in infarct volume and neurological deficit scores, with reduced oxidative stress markers and preserved BBB integrity.

Kumar et al. (2023) "Phytochemical profiling and in vitro antioxidant activity of Merremia tridentata: HPLC quantification of scopoletin and flavonoids," Natural Product Research, provides quantitative data for scopoletin, quercetin, and luteolin, and correlates their content with DPPH and ABTS radical scavenging activity.

Iyer and Nair (2024) "Hepatoprotective activity of Merremia tridentata against paracetamol-induced hepatotoxicity in rats," Indian Journal of Experimental Biology, demonstrates significant reductions in liver enzymes and improvement in histopathological architecture.

Traditional Knowledge Documentation

The Ayurvedic Pharmacopoeia of India includes a monograph for Prasarini (Merremia tridentata), documenting the classical indications, macroscopic and microscopic characteristics, and quality standards. The Traditional Knowledge Digital Library (TKDL) contains multiple formulations.

18. Disclaimer

Merremia tridentata has demonstrated anticonvulsant activity in animal models. It should never be used as a substitute for prescribed antiepileptic medication. The unsupervised substitution or discontinuation of antiepileptic drugs can lead to breakthrough seizures, status epilepticus, and death. Any consideration of this plant as an adjunctive therapy for epilepsy must be undertaken under the direct supervision of a qualified neurologist.

This information is for educational and academic purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Pregnant and nursing women should avoid internal use due to the complete absence of reproductive safety data.

Individuals taking prescription antiepileptic drugs, anticoagulants, or CNS depressants should consult a qualified healthcare practitioner before use.

Do not discontinue or modify the dose of prescribed medications without consulting your doctor.

Always consult a qualified healthcare practitioner before using any plant for medicinal purposes.